Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

durable polymer

  • Home
  • durable polymer
Comparing Long-Term Outcomes of Biodegradable vs. Durable Polymer Everolimus-Eluting Stents in STEMI: Insights from the CONNECT Trial
Posted inCardiology news Specialties

Comparing Long-Term Outcomes of Biodegradable vs. Durable Polymer Everolimus-Eluting Stents in STEMI: Insights from the CONNECT Trial

Posted by MedXY By MedXY 08/13/2025
The CONNECT trial demonstrates no significant difference in neoatherosclerosis rates 3 years post-STEMI between biodegradable and durable polymer everolimus-eluting stents, challenging assumptions about biodegradable polymers' superiority.
Read More
  • Safety of Biopsy in Pheochromocytoma and Paraganglioma: What a Global Study Found
  • Heart Failure Medication Adherence Depends Less on Motivation Than on Whether Treatment Fits Daily Life
  • Beyond Neuronal Injury: Serum Neurofilament Light Chain as a Prognostic Biomarker for Cardiovascular Outcomes in Atrial Fibrillation
  • Cardiovascular Benefit of CPAP May Be Greater in High-Risk Obstructive Sleep Apnoea
  • Drug-Eluting Resorbable Scaffold Maintains a 3-Year Patency Advantage Over Angioplasty in Infrapopliteal CLTI
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号

  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care depression diabetes epidemiology health heart failure Hypertension immunotherapy inflammation MASLD mental health metformin Mortality multiple myeloma myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prevention prostate cancer public health randomized clinical trial randomized trial SGLT2 inhibitors stroke targeted therapy type 1 diabetes type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top
Sign in